Citius Pharma Posts $21.2M Q3 Loss, Announces $36.5M Subsidiary Raise & $5M Offering
CTXR is trading near its 52-week low of $0.57 (7.0% above the low).
Summary
Citius Pharmaceuticals reported a Q3 FY2026 net loss of $21.23 million, primarily driven by a $19.7 million contract cancellation fee. Concurrently, the company announced significant financing, including a raise of up to $36.5 million for its Citius Oncology subsidiary and a $5 million registered direct offering for the parent company. This news provides more specific details on the financing mentioned in yesterday's 8-K and follows a 10-Q filing that highlighted a Q2 net loss and a going concern warning. The combined $41.5 million in new capital is highly dilutive given the company's small market capitalization, but it is crucial as the company projects its cash runway only extends through November 2026. Traders will be closely watching the impact of this dilution and the company's ability to execute on its product pipeline and commercialization efforts to extend its financial viability.
At the time of this announcement, CTXR was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.57 to $2.48. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.